which involved around 800 patients treated with semaglutide or placebo on top of standard care and followed for 72 weeks. MASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback